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Purpose of the study
The standard duration of HCV treatment is 24–48 weeks,
based on the genotype. New Canadian guidelines allow
for a shorter duration to be considered, especially in the
absence of predictors of a poor response and in the pres-
ence of a rapid virologic response (RVR). With this in
mind, we have compared the efficacy of shorter vs. stand-
ard duration of HCV treatment in IDUs enrolled in an
observational modified directly observed therapy (DOT)
inner city cohort.
Methods
All HCV-infected patients enrolled in the Pender Commu-
nity Health Center HCV program were considered for
enrolment in this study. Patients eligible for treatment
according to contemporary Provincial guidelines were ini-
tiated on weekly pegylated interferon along with ribavirin
800–1200 mg/day (according to weight/genotype) with
the interferon administered as DOT and the ribavirin dis-
pensed weekly. Adherence and toxicity were monitored
weekly, while efficacy was monitored by measurement of
HCV-RNA at weeks 4, 12, at end of treatment (ETR), and
6 months later (to document a sustained virologic
response, SVR). Patients completing the standard course
of treatment constituted the control group, while those
discontinuing early due to toxicity or other factors were
the non-randomized experimental group, with SVR docu-
mented 6 months after the actual termination of therapy.
Summary of results
Among the 32 patients who received treatment (27 males,
20 geno 2/3), 19 (59%) achieved SVR (16 male, 15 geno
2/3), 14/32 received standard and 18/32 received shorter
course of therapy. In the latter group, success rate was 8/
18 (44%) and was higher in those with genotype 2/3 (6/
9 vs. 2/9 for geno 1); 3/4 who had RVR achieved SVR and
4/4 who had no RVR did not achieve SVR. In contrast, in
those completing a standard course of therapy, success
rate was 9/14 (64%) and was comparable in geno 2/3 (9/
11) vs. geno 1 (2/3). The median duration of therapy in
the short course group was 15.5 weeks (range 1–6). The
main reasons for early discontinuation were toxicity
(eight), lack of virologic response (five), addiction-related
issues (five).
Conclusion
Shorter duration of treatment of HCV can be successful in
IDUs, particularly if the infection is with HCV genotype 2/
3 and an RVR can be documented. Although the shorter
duration of therapy cannot yet be recommended as a
standard of care, these data may help inform therapeutic
decisions in the face of inevitable premature discontinua-
tion of therapy.
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